外源性及内源性生长抑素对链佐霉素糖尿病小鼠血清胰岛素的作用

已经证明用链佐霉素(简称 STZ)可诱发小鼠产生低胰岛素糖尿病,本工作用外源性注射生长抑素(简称 SS)和用半胱胺特异性耗竭内源性 SS 的方法,观察 SS 对 STZ 糖尿病小鼠血清胰岛素的影响。在注射 STZ(60mg/kg,ip)前10min 分别皮下注射 1μg/kg,5μg/kg,10μg/kg 的 SS 可预防 STZ 诱发的血清低胰岛素作用,并呈剂量-效应关系。注射半胱胺(300mg/kg,SC)24h 后再连续5d 皮下注射半量半胱胺维持,胰腺组织匀浆中的 SS 含量经放免测定鉴定已基本被耗竭。在实验的第7,9,11,16d 胰腺 SS 含量仍然维持在比对照组为低的水平,给这种小鼠注射 STZ,其血清胰岛素降低程度比仅接受 STZ 小鼠的大,此外,给耗竭胰腺内 SS的小鼠注射不足以引起高血糖的 STZ 也引起了血糖大大升高。以上结果表明,不仅外源性 SS有预防链佐霉素诱发的小鼠低血清胰岛素发生的作用,胰腺组织中的内源性 SS 也可能是一个对胰岛 B 细胞起保护作用的因素。     

消炎痛对四氧嘧啶引起的大鼠糖尿病的保护作用

本工作观察了预先给予消炎痛对四氧嘧啶引起的糖尿病大鼠血糖、血清胰岛素和胰高血糖素浓度的影响。结果表明:预先皮下注射消炎痛能使糖尿病大鼠血糖浓度明显降低,并且具有明显的量效关系。在消炎痛剂量5,10,15mg/kg时,注射四氧嘧啶48h后血糖浓度由对照组的591.5±38.2mg％分别降低到559.1±53.2,463.2±16.6和266.6±29.9mg％。在注射消炎痛10mg/kg的实验组,血清胰岛素浓度由对照组的10.5±2.7μU/ml增加到31.9±7.0μU/ml,胰高血糖素由对照组的550.0±27.0pg/ml降低到303.1±22.9pg/ml。组织学观察结果表明,消炎痛对四氧嘧啶引起的大鼠胰岛β细胞的损伤具有显著的保护作用。     

迷走神经—胰岛素系统 Ⅲ.假饲对糖耐量的影响及其机制

本工作用具有食道瘘的狗,观察假饲对糖耐量的影响并分析其机制。糖耐量测验的方法系由静脉注入40%葡萄糖溶液0.5克/千克体重。在注射前以及从注射葡萄糖时开始,每隔15、30、45、60、90及120分钟,分别由静脉取血,分析血糖浓度。假饲是在注射葡萄糖后立即开始的,假饲时间一般为14分钟。实验结果如下:(一)正常糖耐量曲线(不进行假饲)一般是相当恒定的。由静脉注射葡萄糖后15分钟,血糖浓度平均为165毫克%,并且一般在注射后60—90分钟内血糖浓度即恢复至注射前的水平。(二)当由静脉注射葡萄糖后立即进行假饲,结果使正常糖耐量显著增加,也就是使正常糖耐量曲线呈显著的减退性变化:血糖浓度在注射后的15分钟时,平均最高仅达138毫克%,并且在注射后45—60分钟内血糖浓度即恢复至原有水平。(三)当切断膈上的两侧迷走神经或切除胰腺的一切外来神经后,重复以上实验,结果假饲对糖耐量并无影响。因此,本工作更较明确地证明:假饲的进食动作确能唤起中枢神经系统的兴奋,通过迷走神经反射地引起胰岛素的分泌。     

脑室内注射促甲状腺素释放激素(TRH)对家兔血糖及胰岛素水平的影响

本工作用雄性家兔进行实验。由脑内埋藏套管向侧脑室注射各种浓度的 TRH 溶液各40μl,在注射后的15、30、45、60、120min 分别取血测定血糖和血清胰岛素的水平,结果如下:(1)将生理盐水和佐剂甘露醇溶液注入侧脑室,并不引起血糖浓度的明显改变。(2)将 TRH 注入侧脑室可引起血糖浓度明显升高,且与剂量有依赖关系,阈剂量为0.5μg,最大有效剂量为4μg。在注射后15min,血糖开始升高,30-45min 达到峰值,60min 以后开始恢复。将等量的 TRH 注入静脉,血糖浓度无明显改变。(3)将 TRH 注入侧脑室还引起血清胰岛素水平的升高,它也与 TRH 的剂量有依赖关系。但血清胰岛素水平的升高较血糖反应出现得晚,因而前者极可能是后者的继发反应。     

胰岛素对β细胞胰岛素分泌的反馈影响

目的:探讨不同浓度外源性胰岛素在不同浓度葡萄糖情况下对βTC-3细胞胰岛素分泌的影响。方法:取对数生长期的βTC3细胞分三组,即低糖组、中糖组、高糖组(葡萄糖浓度分别取1.0mmol/L、3.0mmol/L、20.0mmol/L)。每组分0、5、10、15、100、500、5000和50000μU/ml胰岛素八个亚组(其中0μU/ml作为对照组)。刺激10分钟后取上清液测C肽。结果:在高糖组中,C肽分泌量无明显差异;在中糖组中,10μU/ml和15μU/ml两组相对对照组C肽分泌量显著增加,50000μU/ml组C肽分泌量则相对对照组出现减少,其余3个亚组无明显改变;在低糖组中,C肽分泌量除5000μU/ml组减少外,其它亚组C肽分泌量无明显差异。结论:胞外胰岛素在适宜葡萄糖浓度时,对βTC3细胞胰岛素分泌的反馈影响呈剂量依赖关系。     

四种胃肠激素对链佐霉素诱发的小鼠高血糖的影响

本实验用腹腔注射链佐霉素(Streptozotocin简称STZ)方法破坏小鼠胰岛B细胞以诱发高血糖,观察生长抑素(Somatostatin,SS)、神经降压素(neurotensin,NT)、胰高血糖素(glucagon,GC)和促甲状腺素释放激素(TRH)4种胃肠激素对小鼠高血糖的影响。在每天腹腔注射STZ(60mg/kg)前10分钟分别经皮下注射上述4种胃肠激素,连续注射5天,在实验的第1,6,8,10,15天取血测血清葡萄糖浓度,对照组注射生理盐水(NS)。结果发现:(1)预先注射SS和NT可不同程度地抑制由STZ引起的实验性高血糖,并呈剂量一效应关系,(2)预先注射GC和TRH,血糖浓度仍明显升高,与NS对照组比较无显著差异,(3)取注射STZ后第15天的高血糖小鼠(血糖高于350mg％者)分为8组,分别以SS和NT作治疗性注射,每天一次共5日,并未见对小鼠高血糖有缓解效果;(4)正常小鼠单独皮下注射NS、SS、NT、GC、和TRH,每天一次连续5天,在注射后15天内未见对血糖水平有明显影响。以上结果提示:预防性注射SS和NT可显著抑制由STZ诱发的高血糖的产生。     

八肽胆囊收缩素对链佐霉素引起的小鼠糖尿病的保护作用

用小剂量多次腹腔注射链佐霉素的方法破坏胰岛β细胞,造成小鼠糖尿病,其主要表现为血糖升高和血清胰岛素浓度下降。在每次注射链佐霉素前10—15min,由皮下注射 CCK-8(100μg/kg),可使链佐霉素的损伤作用減轻或不出现:小鼠血糖浓度由对照组的518.9±53.6mg%降低到267.1±16.8mg%,糖尿病发病率由83.3%降到30%;血清胰岛素浓度基本正常,表明 CCK-8对链佐霉素引起的糖尿病有一定的预防作用。用链佐霉素造成高血糖后,再用 CCK-8作治疗性注射,不能减轻高血糖的程度,表明 CCK-8无治疗作用。CCK-8对正常小鼠的血糖及胰岛素水平也无明显影响。以上结果提示,CCK-8对胰岛β细胞可能具有直接保护作用。     

侧脑室注射胰高血糖素对兔血浆自由脂肪酸、血糖及胰岛素浓度的影响

胰高血糖素是一种脑-肠肽,但它在脑中的生理作用尚不清楚。本工作在家兔侧脑室埋藏慢性套管,并通过注射20μl含0.5—5μg的胰高血糖素溶液,在注射后的15、45、75、105分钟各取血样测定血糖、血浆自由脂肪酸(FFA)和胰岛素的浓度。结果发现:(1)对血糖及血浆胰岛素浓度无明显影响;(2)能引起血浆 FFA 浓度降低,且与剂量有依赖关系,在注射后的45分钟,FFA 降低最明显,以后逐渐恢复;(3)皮下注射阿托品(0.2mg/kg)或静脉注射酚妥拉明(5mg/kg)均不能消除侧脑室注射胰高血糖素降低 FFA 的作用;(4)静脉注射心得安(5mg/kg)能阻断侧脑室注射胰高血糖素的降低 FFA 的作用。这似表明脑中的胰高血糖素可能参与脂代谢的调节,并可能是通过肾上腺素β-受体起作用的。     

生长抑素可预防链佐霉素诱发的大鼠胰岛 B 细胞分泌功能的损伤

本工作通过测定大鼠血清、胰腺灌流液以及肤腺组织中胰岛素含量,观察生长抑素(SS)对链佐霉素(STZ)诱发的实验性糖尿病的作用。结果如下:皮下注射生理盐水后10min,再向腹腔注射链佐霉素(35mg/kg),24h 后大鼠血清胰岛素浓度明显降低。胰腺组织匀浆中的胰岛素含量也明显减少。如若在注射链佐霉素前10min 皮下注射生长抑素,则可有效地防止上述两项指标的改变,(NS STZ)和(SS STZ)两组之间具有显著差异。单独注射生长抑素,24h 后血清胰岛素及胰腺组织中胰岛素含量与正常对照无明显差异。用分离的大鼠胰腺作体外灌流,观察到:NS STZ 组大鼠灌流胰腺对19.7mmol/L 的高浓度葡萄糖刺激无胰岛素释放反应,而 SS STZ 组大鼠的胰腺对高浓度葡萄糖有反应性,刺激后出现胰岛素分泌峰。上述结果表明,SS(30μg/kg)预防性注射可以防止 STZ 引起的胰岛 B 细胞分泌功能的障碍。     

不同剂量熊果酸干预糖尿病小鼠视网膜病变的作用及机制研究

目的:探究不同剂量熊果酸(UA)干预糖尿病小鼠视网膜病变的作用及机制。方法:选取雄性健康C57BL/6小鼠60只,其中50只按50 mg/kg的剂量一次性往小鼠尾静脉注射新鲜配置的四氯嘧啶生理盐水溶液构建小鼠糖尿病视网膜病变模型,随机分为5组,每组10只,分别为模型组、阳性对照组(小鼠玻璃体注射3μL 40 mg/m L的曲安奈德),低剂量UA干扰组(小鼠玻璃体注射3μL剂量为0.5μg/μL的UA)、中剂量UA干扰组(小鼠玻璃体注射3μL剂量为1.0μg/μL的UA),高剂量UA干扰组(小鼠玻璃体注射3μL剂量为2.0μg/μL的UA),余下10只小鼠作为正常对照组。观察各组小鼠对胰岛素敏感性、视网膜内糖代谢情况、小鼠视网膜神经节细胞(RGCs)凋亡情况,比较各组小鼠视网膜组织中血管内皮生长因子(VEGF)、环氧化酶-2(COX-2)、基质金属蛋白酶2(MMP-2)蛋白及其mRNA的表达情况。结果:建模后,正常对照组胰岛素抵抗指数(HOMA-IR)、视网膜含糖量、葡萄糖转运体-1(GLUT-1)与葡萄糖转运体-3(GLUT-3)含量、RGCs凋亡率、视网膜组织中VEGF、COX-2、MMP-2蛋白及其mRNA的表达量低于模型组(P0.05);经干扰后,阳性对照组、不同剂量UA干扰组HOMA-IR、视网膜含糖量、GLUT-1、GLUT-3的含量、RGCs凋亡率、视网膜组织中VEGF、COX-2、MMP-2蛋白及其mRNA的表达量低于模型组(P0.05),且随UA干扰剂量的升高而降低(P0.05)。结论:UA能够降低HOMA-IR和视网膜糖代谢能力,抑制RGCs的凋亡,对VEGF、COX-2、MMP-2蛋白及其mRNA的表达具有一定的抑制作用,高剂量UA对糖尿病小鼠视网膜病预防治疗效果较好。     

一次性静脉注射高剂量链脲佐菌素建立1型糖尿病小型猪模型

目的：探讨通过一次性注射高剂量链脲佐菌素（ streptozotocin,STZ）方法建立1型糖尿病小型猪模型的可行性。方法中华实验小型猪耳缘静脉一次性注射链脲佐菌素溶液150 mg/kg,分别在给药前和给药后10 min、30 min、90 min、第1天、第2天、第3天和第7天空腹采集静脉血,动态监测空腹血糖,并利用静脉糖耐量实验和C肽释放实验对模型进行鉴定。结果给药后第1天开始,模型组空腹血糖明显升高并始终维持在16.7～20.6 mmol/L的浓度范围,达到糖尿病标准;静脉葡萄糖耐量试验和C肽释放实验结果表明,静脉注射体积分数50％的葡萄糖1 h后模型猪血糖浓度高于11.1 mmol/L,2 h后未能恢复至空腹血糖水平;而胰岛素和C肽在注入葡萄糖后基本未发生任何反应,始终保持痕量水平。结论一次性静脉注射大剂量链脲佐菌素的方法能够成功建立1型糖尿病小型猪模型。     

Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection

Prior studies have demonstrated the effectiveness of noninvasive transdermal insulin delivery using a cymbal transducer array. In this study the physiologic response to ultrasound mediated transdermal insulin delivery is compared to that of subcutaneously administered insulin. Anesthetized rats (350-550 g) were divided into four groups of four animals; one group representing ultrasound mediated insulin delivery and three representing subcutaneously administered insulin (0.15, 0.20, and 0.25 U/kg). The cymbal array was operated for 60 minutes at 20 kHz with 100 mW/cm2 spatial-peak temporal-peak intensity and a 20% duty cycle. The blood glucose level was determined at the beginning of the experiment and, following insulin administration, every 15 minutes for 90 minutes for both the ultrasound and injection groups. The change in blood glucose from baseline was compared between groups. When administered by subcutaneous injection at insulin doses of 0.15 and 0.20 U/kg, there was little change in the blood glucose levels over the 90 minute experiment. Following subcutaneous administration of insulin at a dose of 0.25 U/kg, blood glucose decreased by 190 +/- 96 mg/dl (mean +/- SD) at 90 minutes. The change in blood glucose following ultrasound mediated insulin delivery was -262 +/- 40 mg/dl at 90 minutes. As expected, the magnitude of change in blood glucose between the three injection groups was dependant on the dose of insulin administered. The change in blood glucose in the ultrasound group was greater than that observed in the injection groups suggesting that a higher effective dose of insulin was delivered.     

The effect of magnesium deficiency on glucose stimulated insulin secretion in rats

Weanling Sherman rats were pair-fed for 8 days on a control or a magnesium deficient diet containing 70.5% sucrose. After a 12-hour fast, the rats were injected intraperitoneally with glucose (250 mg/100 g body weight) and arterial blood was drawn at 0, 15, 30, 60, 90 minutes after injection. Before glucose loading, in magnesium deficient rats, plasma magnesium levels were significantly increased. The plasma triglyceride concentration was significantly higher in magnesium deficient rats compared to controls. After glucose loading, in the control group, the plasma insulin concentrations increased to 67.9 +/- 5.8 microU/ml at 15 minutes and returned to pretreatment levels by 30 minutes; in the magnesium-deficient rats, the plasma insulin levels were significantly lower at 15 minutes 32.9 +/- 5.6 microU/ml (P less than 0.01) and returned more slowly to the pre-challenge level. No significant differences were observed in plasma glucose levels between the two groups of rats.     

Failure of exogenous insulin to inhibit insulin secretion in man

In order to explore whether or not the negative feedback mechanism of insulin per se on insulin secretion exists in man, changes in plasma C-peptide immunoreactivity (CPR), as an index of pancreatic B cells secretory function, were studied in 6 nonobese healthy volunteers in the presence of high circulating levels of exogenous insulin. 10% glucose was infused concurrently so as to maintain blood sugar at the basal level. The insulin-glucose infusion was maintained for 120 minutes, achieving mean plasma levels of 140-180 mu1/ml. After this period, the insulin infusion was continued at the same rate for an additional 10 minutes while the glucose was omitted. Despite the elevated level of circulating insulin, no significant change in plasma CPR concentration was observed so long as the blood sugar was maintained at the basal levels. Following cessation of the glucose infusion, the plasma CPR levels declined with a decrease in blood sugar level. Under the conditions of the present study, no inhibitory effect of exogenous insulin on the secretory function of the B cells was noticed.     

Increase in insulin secretion induced by plasma from mice injected with allogeneic lymphocytes

Plasma from BALB/c mice bled 90 minutes after allogeneic lymphocyte injection significantly rises glucose induced insulin secretion. This rise is observed in pancreas either from non-treated or from allogeneized mice. This rise is time and dose-dependent. An 1/40 dilution is enough to bring about a significant increase on insulin secretion. This effect is seen when mice are bled between 60 and 180 minutes after injection with a maximum effect at 90-120 minutes. Plasma from BALB/c mice injected with C57BL/6 J lymphocytes rises insulin secretion from BALB/c, C57BL/6 J, C3h and C57BL/KsJ mice pancreas. Plasma from streptozotocin diabetic BALB/c mice and from genetically diabetic C57BL/KsJ mdb-mdb mice injected with allogeneic lymphocytes stimulates glucose induced insulin secretion but to a lesser extent than plasma from normal non-diabetic mice does.     

Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children

A peak period of hyperglycaemia in insulin-dependent diabetics occurs after breakfast. A randomised crossover study was performed on nine diabetic children at home to study the effect of varying the time of their morning mixed injection of Monotard and Actrapid insulin on this hyperglycaemic peak. Performing the study at home minimised the children''s stress.After diabetic control had been improved children injected their insulin 30 minutes (early injection) or five minutes (late injection) before breakfast on two consecutive Saturday mornings. Blood samples were taken at 30-minute intervals over 3½ hours and analysed for concentrations of glucose, insulin, C-peptide, pyruvate, lactate, alanine, and ketones. Diet, insulin dose, and exercise were kept the same on both test days.The mean blood glucose concentration at breakfast (0 minutes) was 11 mmol/l after the early injection and 10 mmol/l after the late injection. Subsequent concentrations were consistently lower with the early injection regimen than the late regimen. The greatest difference between values in the two groups was 3·7 mmol/l at 150 minutes. Mean plasma insulin concentrations were lower in the children on the early regimen than in those on the late regimen at 30 minutes before breakfast but higher at 0 minutes and thereafter. There were no significant differences in mean concentration of intermediary metabolites between the two injection regimens. These were mainly within the normal range for healthy young adults except for the ketone concentrations, which were raised with both injection regimens until 180 minutes after breakfast.These results suggest that the timing of the morning injection of insulin is important in the control of postprandial hyperglycaemia in diabetic children.     

Recovery from insulin-induced hypoglycemia after saccharose or glucose administration

This study compared the effects of saccharose and glucose on the recovery from insulin hypoglycemia. 17 normal volunteers (12 men, 5 women, 25-40 years old) received the same dose (0.1 IU i.v.) of semisynthetic rapid-acting human insulin on two different days after an overnight fast. Blood glucose and C peptide were measured in venous blood samples before as well as at regular time intervals after insulin administration. 30 min after the injection, 20 g saccharose or 20 g glucose p.o. (diluted in water) were given. The mean glucose values were at most time intervals higher after glucose than after saccharose administration. In addition, glucose ingestion resulted in an earlier and steeper blood glucose rise (mean recovery rates during the first 5 min 3.10 and 1.38 mg/dl/min for glucose and saccharose, respectively). The C peptide values decreased progressively and did not achieve baseline levels even at 120 min in spite of blood sugar normalization. It is concluded that glucose acts faster than saccharose in insulin-induced hypoglycemia. Exogenous insulin results in a prolonged depression of C peptide which lasts longer than the hypoglycemic effect.     

Simplification of the intravenous glucose tolerance test (ivGTT) in rats

A simplified technique was established for the intravenous glucose tolerance test (ivGTT) in unanesthetized rats. In order to evaluate the relation between insulin secretion, glucose load and glucose disappearance rate, precatheterized rats were given glucose ranging in dose from 0.25 to 2.0 g/kg bw by intravenous injection. A highly linear correlation was observed in glucose disappearance rate during a period of 4-32 min. A glucose load greater than 0.5 g/kg ow induced a maximum response in insulin secretion. Small blood samples were collected using the orbital bleeding technique at 4, 16 and 28 minutes after a glucose load of 1.0 g/kg bw had been given and then T1/2, the time taken for the glucose level to fall by one half, was calculated. The mean T1/2 was significantly longer in alloxan- or cyproheptadin-diabetic rats than that in the intacts. These data indicate that a glucose load of 1.0 g/kg administered by intravenous injection with the T1/2 calculated between 4 and 32 minutes would provide an accurate means of assessing pancreatic endocrine function.     

Oral Glucose Tolerance and Related Factors in a Normal Population Sample—I. Blood Sugar,Plasma Insulin,Glyceride, and Cholesterol Measurements and the Effects of Age and Sex

Oral glucose tolerance tests were performed on 220 people, a representative sample of the employees of a large pharmaceutical company. Blood sugar and plasma immunoreactive insulin levels were measured on each sample of venous blood obtained before and at half-hourly intervals for two hours after 50 g. of glucose by mouth; plasma cholesterol and glycerides were measured on the fasting sample only.Women had higher mean insulin levels throughout the test, though their mean blood sugar levels were higher only at 90 and 120 minutes. In both sexes there were positive correlations between age and the levels of blood sugar, plasma cholesterol, and plasma glycerides. Though the levels of glucose rose with age, those of insulin did not.     

Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.

OBJECTIVE--To compare the rate of absorption from subcutaneous tissue and the resulting hypoglycaemic effect of iodine-125 labelled soluble human insulin and a monomeric insulin analogue derived by recombinant DNA technology. DESIGN--Single blind randomised comparison of equimolar doses of 125I labelled soluble human insulin and insulin analogue. SETTING--Study in normal people at a diabetes research unit and a university department of medical physics. SUBJECTS--Seven healthy male volunteers aged 20-39 not receiving any other drugs. INTERVENTIONS--After an overnight fast and a basal period of one hour two doses (0.05 and 0.1 U/kg) of 125I labelled soluble human insulin and insulin analogue were injected subcutaneously into the anterior abdominal wall on four separate days. END POINT--To find a fast acting insulin for meal related requirements in insulin dependent diabetics. MEASUREMENTS and main results--Residual radioactivity at the injection site was measured continuously for the first two hours after injection of the 125I labelled preparations and thereafter for five minutes simultaneously with blood sampling. Frequent venous blood samples were obtained over six hours for determination of plasma immunoreactive insulin, insulin analogue, glucose, and glucagon values. Time to 50% of initial radioactivity at the injection site for the insulin analogue compared with soluble insulin was 61 v 135 minutes (p less than 0.05) with 0.05 U/kg and 67 v 145 minutes (p less than 0.001) with 0.1 U/kg. Concentrations in plasma increased faster after the insulin analogue compared with soluble insulin, resulting in higher plasma concentrations between 10 and 150 minutes (0.001 less than p less than 0.05) after 0.05 U/kg and between 40 and 360 minutes (0.001 less than p less than 0.05) after 0.1 U/kg. The hypoglycaemic response to insulin analogue was a plasma glucose nadir at 60 minutes with both doses compared with 90 and 120 minutes with soluble insulin at 0.5 and 0.1 U/kg respectively. The response of glucagon substantiated the earlier and more dramatic hypoglycaemic effect with the insulin analogue. CONCLUSIONS--The much faster absorption from subcutaneous tissue of the disubstituted monomeric insulin analogue compared with soluble insulin suggests that the analogue may be a potential candidate for rapid insulin delivery after subcutaneous bolus injection.